» Articles » PMID: 28655998

Exosomes from Melatonin Treated Hepatocellularcarcinoma Cells Alter the Immunosupression Status Through STAT3 Pathway in Macrophages

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2017 Jun 29
PMID 28655998
Citations 54
Authors
Affiliations
Soon will be listed here.
Abstract

Immunosuppression is a significant factor in the progression of tumor invasion and metastasis. Melatonin, a well-known hormone, has certain cytotoxic and immune regulatory effects to inhibit tumor function. Exosomes are small membrane vesicles released by many kinds of cells, which contain different macromolecules, such as mRNAs and microRNAs (miRNAs), and proteins that can mediate communications between cells. Tumor-derived exosomes may cause immunosuppression, however, it is unknown whether melatonin can attenuate an immunosuppressive status by altering the function of tumor-derived exosomes. In the present study, we evaluated the effects of hepatocellularcarcinoma-derived exosomes (Exo-con) and exosomes derived from hepatocellularcarcinoma cells treated with 0.1 mM melatonin (Exo-MT), on the expression of inflammatory factors and programmed death ligand 1(PD-L1) by co-culturing Exo-con and Exo-MT, respectively, with macrophages differentiated from THP-1 cells or RAW264.7 cells. Our results indicate that Exo-MT can downregulate the expression of PD-L1 on macrophages while Exo-con can upregulate the expression of PD-L1 through flow cytometry and immunofluorescence analysis. In addition, Exo-con upregulates the secretion of cytokines, such as IL-6, IL-10, IL-1β, and TNF-α in macrophages. Accordingly, Exo-MT could attenuate the high expression of these inflammatory cytokines. Furthermore, experiments confirmed the results found . PD-L1 expression and cytokine secretion were lower in the Exo-MT group compared with those in the Exo-con group. Working to identify a specific mechanism, our research shows that Exo-MT decreases STAT3 activation compared to the Exo-con group. In summary, we found exosomes from melatonin treated hepatocellularcarcinoma cells alters the immunosupression status through STAT3 pathway in macrophages. Our study may provide a new avenue to investigate the mechanisms of melatonin in regulating an immunosuppressive status.

Citing Articles

Exosomes as mediators of tumor immune escape and immunotherapy in hepatocellular carcinoma.

Guan M, Wang M, Wang W, Li C, Yao L, Zhu H Liver Res. 2025; 6(3):132-138.

PMID: 39958202 PMC: 11791807. DOI: 10.1016/j.livres.2022.08.001.


Melatonin, an Antitumor Necrosis Factor Therapy.

Alvarez-Lopez A, Cruz-Chamorro I, Lardone P, Bejarano I, Aspiazu-Hinostroza K, Ponce-Espana E J Pineal Res. 2024; 77(1):e70025.

PMID: 39740227 PMC: 11685806. DOI: 10.1111/jpi.70025.


Pre-metastatic niche: formation, characteristics and therapeutic implication.

Wang Y, Jia J, Wang F, Fang Y, Yang Y, Zhou Q Signal Transduct Target Ther. 2024; 9(1):236.

PMID: 39317708 PMC: 11422510. DOI: 10.1038/s41392-024-01937-7.


Tumor-associated exosomes in cancer progression and therapeutic targets.

Liu X, Wu F, Pan W, Liu G, Zhang H, Yan D MedComm (2020). 2024; 5(9):e709.

PMID: 39247621 PMC: 11380050. DOI: 10.1002/mco2.709.


Extracellular Vesicles, Circadian Rhythms, and Cancer: A Comprehensive Review with Emphasis on Hepatocellular Carcinoma.

Fekry B, Ugartemendia L, Esnaola N, Goetzl L Cancers (Basel). 2024; 16(14).

PMID: 39061191 PMC: 11274441. DOI: 10.3390/cancers16142552.


References
1.
Calvo J, Gonzalez-Yanes C, Maldonado M . The role of melatonin in the cells of the innate immunity: a review. J Pineal Res. 2013; 55(2):103-20. DOI: 10.1111/jpi.12075. View

2.
Liu F, Dai W, Li C, Lu X, Chen Y, Weng D . Role of IL-10-producing regulatory B cells in modulating T-helper cell immune responses during silica-induced lung inflammation and fibrosis. Sci Rep. 2016; 6:28911. PMC: 4926212. DOI: 10.1038/srep28911. View

3.
Fan L, Sun G, Ma T, Zhong F, Wei W . Melatonin overcomes apoptosis resistance in human hepatocellular carcinoma by targeting survivin and XIAP. J Pineal Res. 2013; 55(2):174-83. DOI: 10.1111/jpi.12060. View

4.
Zou W, Wolchok J, Chen L . PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016; 8(328):328rv4. PMC: 4859220. DOI: 10.1126/scitranslmed.aad7118. View

5.
Atretkhany K, Drutskaya M, Nedospasov S, Grivennikov S, Kuprash D . Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment. Pharmacol Ther. 2016; 168:98-112. DOI: 10.1016/j.pharmthera.2016.09.011. View